1,321 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Sivia Capital Partners LLC

Sivia Capital Partners LLC purchased a new position in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,321 shares of the company’s stock, valued at approximately $261,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Bell Private Wealth Management LLC grew its stake in shares of Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares during the last quarter. Independence Bank of Kentucky grew its stake in shares of Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after buying an additional 130 shares during the last quarter. Private Wealth Management Group LLC purchased a new stake in shares of Zoetis in the 4th quarter worth approximately $33,000. Ramirez Asset Management Inc. purchased a new stake in shares of Zoetis in the 3rd quarter worth approximately $35,000. Finally, Gladius Capital Management LP purchased a new stake in shares of Zoetis in the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of several recent research reports. Barclays cut their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Stifel Nicolaus lowered their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, April 30th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. HSBC lowered their price target on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $211.75.

Zoetis Price Performance

Shares of Zoetis stock opened at $170.87 on Tuesday. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The stock’s fifty day moving average is $165.85 and its 200 day moving average is $179.50. The stock has a market cap of $77.97 billion, a P/E ratio of 32.92, a P/E/G ratio of 2.65 and a beta of 0.89. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The company had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. During the same period last year, the firm earned $1.31 EPS. Zoetis’s revenue for the quarter was up 9.5% compared to the same quarter last year. Sell-side analysts anticipate that Zoetis Inc. will post 5.76 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be paid a $0.432 dividend. The ex-dividend date is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.01%. Zoetis’s payout ratio is presently 33.33%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the transaction, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.